Case number 2022-2153
Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 20, 2024 | 77 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [1012021] [22-2153, 23-1952] [MVH] [Entered: 06/20/2024 09:38 AM] (1) |
| Jun 13, 2024 | 76 | ORDER filed denying [73] petition for panel rehearing and rehearing en banc filed by Salix Pharmaceuticals, Inc., Salix Pharmaceuticals, Ltd., Bausch Health Ireland Ltd. and Alfasigma S.p.A.; denying [74] petition for panel rehearing and rehearing en banc filed by Norwich Pharmaceuticals Inc. By: Per Curiam. Service as of this date by the Clerk of Court. [1010815] [MVH] [Entered: 06/13/2024 10:24 AM] (2) |
| May 15, 2024 | 75 | 13 paper copies of Doc. No. [74], received from Cross-Appellant Norwich Pharmaceuticals Inc.. [1004249] [VDW] [Entered: 05/15/2024 11:48 AM] (0) |
| May 13, 2024 | 74 | Petition for panel rehearing, for en banc rehearing filed by Cross-Appellant Norwich Pharmaceuticals Inc.. Service: 05/13/2024 by email. [1003829] [22-2153] [Chad Landmon] [Entered: 05/13/2024 02:45 PM] (148) |
| May 10, 2024 | 73 | Petition for en banc rehearing, for panel rehearing filed by Appellants Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Bausch Health Ireland Ltd. and Alfasigma S.p.A.. Service: 05/10/2024 by email. [1003633] [22-2153] [William Peterson] [Entered: 05/10/2024 05:59 PM] (56) |
| Apr 14, 2024 | 0 | SALIX PHARMACEUTICALS, LTD. v. NORWICH PHARMACEUTICALS INC. [OPINION] [precedential] (0) |
| Apr 11, 2024 | 71 | OPINION filed for the court by Lourie, Circuit Judge; Chen, Circuit Judge and Cunningham, Circuit Judge. Cunningham, Circuit Judge, dissenting in part. Precedential Opinion. Service as of this date by the Clerk of Court. [996710] [22-2153, 23-1952] [MVH] [Entered: 04/11/2024 10:51 AM] (29) |
| Apr 11, 2024 | 72 | JUDGMENT. AFFIRMED. Terminated on the merits after oral argument. COSTS: No Costs. Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. Service as of this date by the Clerk of Court. [996711] [22-2153, 23-1952] [MVH] [Entered: 04/11/2024 10:52 AM] (1) |
| Jan 8, 2024 | 70 | Submitted after ORAL ARGUMENT to Panel: Lourie, Circuit Judge; Chen, Circuit Judge and Cunningham, Circuit Judge.Arguing counsel: Mr. William R. Peterson for Salix Pharmaceuticals, Inc., Salix Pharmaceuticals, Ltd., Bausch Health Ireland Ltd. and Alfasigma S.p.A. and Mr. Chad A. Landmon for Norwich Pharmaceuticals Inc.Oral Argument Audio available here. [975171] [JCP] [Entered: 01/08/2024 02:08 PM] (0) |
| Dec 1, 2023 | 69 | Response to notice of oral argument from Cross-Appellant Norwich Pharmaceuticals Inc.. Service: 12/01/2023 by email. [967104] [22-2153] [Chad Landmon] [Entered: 12/01/2023 04:24 PM] (1) |
| Dec 1, 2023 | 68 | Response to notice of oral argument from Appellants Salix Pharmaceuticals, Inc., Salix Pharmaceuticals, Ltd., Alfasigma S.p.A. and Bausch Health Ireland Ltd.. Service: 12/01/2023 by email. [967055] [22-2153] [William Peterson] [Entered: 12/01/2023 03:01 PM] (1) |
| Nov 17, 2023 | 67 | NOTICE OF ORAL ARGUMENT. Panel: 2401A. Case scheduled January 8, 2024. Response to Notice of Oral Argument due: 12/01/2023. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [964122] [JCP] [Entered: 11/17/2023 12:55 PM] (2) |
| Nov 15, 2023 | 66 | Amended Entry of Appearance for William R. Peterson; Michael J. Abernathy; Julie S. Goldemberg; Michael T. Sikora; Karon N. Fowler as counsel for Appellants Salix Pharmaceuticals, Inc., Salix Pharmaceuticals, Ltd., Bausch Health Ireland Ltd. and Alfasigma S.p.A.. Service: 11/15/2023 by email. [963691] [22-2153] [Julie Goldemberg] [Entered: 11/15/2023 07:26 PM] (2) |
| Nov 6, 2023 | 65 | RESPONSE of Cross-Appellant Norwich Pharmaceuticals Inc. to Doc No. [61]. Service: 11/06/2023 by email. [961691] [22-2153] [Chad Landmon] [Entered: 11/06/2023 03:43 PM] (2) |
| Nov 3, 2023 | 64 | Notice from Appellants Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Bausch Health Ireland Ltd. and Alfasigma S.p.A. regarding conflicts with oral argument. Service: 11/03/2023 by email. [961300] [22-2153] [William Peterson] [Entered: 11/03/2023 01:50 PM] (4) |
| Nov 3, 2023 | 63 | 6 paper copies of Doc. No. [56] received from Appellants Alfasigma S.p.A., Bausch Health Ireland Ltd., Salix Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd.. [961115] [VDW] [Entered: 11/03/2023 09:19 AM] (0) |
| Nov 2, 2023 | 62 | 6 paper copies of Doc. No. [55] received from Cross-Appellant Norwich Pharmaceuticals Inc.. [961114] [VDW] [Entered: 11/03/2023 09:15 AM] (0) |
| Nov 2, 2023 | 61 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellants Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Alfasigma S.p.A. and Bausch Health Ireland Ltd.. Service: 11/02/2023 by email. [961088] [22-2153] [William Peterson] [Entered: 11/02/2023 07:04 PM] (42) |
| Nov 1, 2023 | 60 | Notice from Cross-Appellant Norwich Pharmaceuticals Inc. regarding conflicts with oral argument. Service: 11/01/2023 by email. [960773] [22-2153] [Chad Landmon] [Entered: 11/01/2023 05:11 PM] (2) |
| Oct 31, 2023 | 59 | Supplementary Media Appendix received on USB from Alfasigma S.p.A., Bausch Health Ireland Ltd., Salix Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd.. Number of copies: 4. [960360] [VDW] [Entered: 10/31/2023 01:55 PM] (0) |
| Oct 31, 2023 | 58 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [960252] [KMH] [Entered: 10/31/2023 10:10 AM] (1) |
| Oct 30, 2023 | 57 | MODIFIED ENTRY: APPENDIX FILED by Appellants Alfasigma S.p.A., Bausch Health Ireland Ltd. and Salix Pharmaceuticals, Ltd.. Service: 10/30/2023 by email. [960094] --[Edited 10/31/2023 by KMH - compliance review complete] [William Peterson] [Entered: 10/30/2023 03:24 PM] (1047) |
| Oct 30, 2023 | 56 | MODIFIED ENTRY: CONFIDENTIAL APPENDIX FILED by Appellants Alfasigma S.p.A., Bausch Health Ireland Ltd., Salix Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd.. Service: 10/30/2023 by email, US mail. [960089]--[Edited 10/31/2023 by KMH - compliance review complete] Paper copies of this brief must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A) [William Peterson] [Entered: 10/30/2023 03:14 PM] (0) |
| Oct 23, 2023 | 55 | MODIFIED ENTRY: REPLY BRIEF FILED by Cross-Appellant Norwich Pharmaceuticals Inc.. Service: 10/23/2023 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [958313] --[Edited 10/30/2023 by KMH - compliance review complete] Paper copies of this brief must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A) [Chad Landmon] [Entered: 10/23/2023 03:35 PM] (35) |
| Oct 18, 2023 | 54 | 6 paper copies of Doc. No. [52] received from Appellants Alfasigma S.p.A., Bausch Health Ireland Ltd., Salix Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd.. [957265] [VDW] [Entered: 10/18/2023 11:12 AM] (0) |
| Oct 13, 2023 | 53 | Paper copies of Appellants' response and reply brief [52] must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A). [956258] [KMH] [Entered: 10/13/2023 02:00 PM] (0) |
| Oct 12, 2023 | 52 | MODIFIED ENTRY: REPLY BRIEF FILED by Appellants Alfasigma S.p.A., Bausch Health Ireland Ltd., Salix Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd.. Service: 10/12/2023 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [956055] --[Edited 10/13/2023 by KMH - compliance review complete] [William Peterson] [Entered: 10/12/2023 06:58 PM] (83) |
| Sep 18, 2023 | 51 | 6 paper copies of Doc. No. [43] received from Amicus Curiae Vanda Pharmaceuticals Inc.. [951332] [VDW] [Entered: 09/20/2023 03:30 PM] (0) |
| Sep 14, 2023 | 50 | ORDER filed granting motion to extend time to file brief [45] to the extent that Salix's response and reply brief is due no later than October 12, 2023, Norwich's reply brief is due no later than 21 days after service of Salix's response and reply brief, and the joint appendix is due no later than seven days after service of Norwich's reply brief. The parties shall file six paper copies of each of these briefs and the joint appendix within three business days after the court completes its compliance review of each of those documents. Service as of this date by the Clerk of Court. [950078] [LMS] [Entered: 09/14/2023 02:56 PM] (2) |
| Sep 14, 2023 | 49 | NOTICE OF NON-COMPLIANCE: The paper copies (Doc. No. [48]) provided by Vanda Pharmaceuticals Inc. are not in compliance with the rules of this court (see attached). Corrected paper copies are due within 5 business days. Service as of this date by the Clerk of Court. [949983] [VDW] [Entered: 09/14/2023 11:45 AM] (1) |
| Sep 13, 2023 | 48 | 6 paper copies of Doc. No. [43] received from Amicus Curiae Vanda Pharmaceuticals Inc.. [949980]. These paper copies are non-compliant. See Doc. No. [49] [VDW] [Entered: 09/14/2023 11:42 AM] (0) |
| Sep 13, 2023 | 47 | RESPONSE of Cross-Appellant Norwich Pharmaceuticals Inc. to Doc No. [45]. Service: 09/13/2023 by email. [949871] [22-2153] [Chad Landmon] [Entered: 09/13/2023 05:48 PM] (9) |
| Sep 12, 2023 | 46 | 6 paper copies of Doc. No. [44] received from Amici Curiae Ocular Therapeutix, Inc. and Regeneron Pharmaceuticals, Inc.. [949761] [VDW] [Entered: 09/13/2023 02:03 PM] (0) |
| Sep 11, 2023 | 45 | MOTION of Appellants Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Bausch Health Ireland Ltd. and Alfasigma S.p.A. to extend the time to 10/16/2023 to file brief. Service: 09/11/2023 by email. [949181] [22-2153] [William Peterson] [Entered: 09/11/2023 03:38 PM] (7) |
| Aug 30, 2023 | 44 | MODIFIED ENTRY: CORRECTED AMICUS BRIEF FILED by Ocular Therapeutix, Inc. and Regeneron Pharmaceuticals, Inc.. Service: 08/30/2023 by email. [946788]--[Edited 09/08/2023 by KMH - compliance review complete] Paper copies of this brief must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A) [Irena Royzman] [Entered: 08/30/2023 01:29 PM] (26) |
| Aug 30, 2023 | 43 | MODIFIED ENTRY: CORRECTED AMICUS BRIEF FILED by Vanda Pharmaceuticals Inc.. Service: 08/30/2023 by email. [946714]--[Edited 09/08/2023 by KMH - compliance review complete] Paper copies of this brief must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A) [Paul Hughes] [Entered: 08/30/2023 11:23 AM] (37) |
| Aug 30, 2023 | 42 | Corrected Entry of Appearance for Paul W. Hughes; Sarah P. Hogarth; Christopher M. Bruno; April E. Weisbruch as counsel for Amicus Curiae Vanda Pharmaceuticals Inc.. Service: 08/30/2023 by email. [946713] [22-2153] [Paul Hughes] [Entered: 08/30/2023 11:22 AM] (2) |
| Aug 29, 2023 | 41 | 6 paper copies of Doc. No. [38] received from Cross-Appellant Norwich Pharmaceuticals Inc.. [946629] [VDW] [Entered: 08/30/2023 09:05 AM] (0) |
| Aug 25, 2023 | 39 | ORDER filed granting the motions, ECF Nos. 31-1 and 35-1, to the extent that, no later than seven days from the date of entry of this order, Regeneron and Vanda are each directed to file a corrected amicus brief resolving the above-identified issue and including the word "corrected" in the title, Fed. Cir. R. 25(i)(2). Service as of this date by the Clerk of Court. [945922] [LMS] [Entered: 08/25/2023 11:36 AM] (2) |
| Aug 25, 2023 | 40 | NOTICE OF NON-COMPLIANCE: The submission of Amicus Curiae Vanda Pharmaceuticals Inc., Entry of Appearance [33], is not in compliance with the rules of this court (see attached). Compliant document due on 09/01/2023. Service as of this date by the Clerk of Court. [945951] [KMH] [Entered: 08/25/2023 12:26 PM] (2) |
| Aug 22, 2023 | 38 | MODIFIED ENTRY: RESPONSE BRIEF FILED by Cross-Appellant Norwich Pharmaceuticals Inc.. Service: 08/22/2023 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [945072] --[Edited 08/25/2023 by KMH - compliance review complete] Paper copies of this brief must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A) [Chad Landmon] [Entered: 08/22/2023 04:58 PM] (89) |
| Aug 2, 2023 | 37 | 6 paper copies of Doc. No. [28] received from Appellants Alfasigma S.p.A., Bausch Health Ireland Ltd., Salix Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd.. [940259] [VDW] [Entered: 08/02/2023 04:16 PM] (0) |
| Aug 1, 2023 | 36 | ORDER Any opposition to the motion [35] shall be filed no later than seven days from the date of issuance of this order. Any reply is due no later than three days from the date of filing of the response. Service as of this date by the Clerk of Court. [939901] [LMS] [Entered: 08/01/2023 03:29 PM] (2) |
| Jul 31, 2023 | 35 | MOTION of Vanda Pharmaceuticals Inc. for leave to file an amicus curiae brief. Service: 07/31/2023 by email. [939707] [22-2153] [Paul Hughes] [Entered: 07/31/2023 09:31 PM] (49) |
| Jul 31, 2023 | 34 | Certificate of Interest for Vanda Pharmaceuticals Inc.. Service: 07/31/2023 by email. [939706] [22-2153] [Paul Hughes] [Entered: 07/31/2023 09:26 PM] (3) |
| Jul 31, 2023 | 33 | Entry of Appearance for Paul W. Hughes; Sarah P. Hogarth; Christopher M. Bruno; April E. Weisbruch as counsel for Vanda Pharmaceuticals Inc.. Service: 07/31/2023 by email. [939644] [22-2153] This document is non-compliant. See Doc No. [40] [Paul Hughes] [Entered: 07/31/2023 04:48 PM] (2) |
| Jul 31, 2023 | 32 | ORDER Any opposition to the motion shall be filed no later than seven days from the date of issuance of this order. Any reply is due no later than three days from the date of filing of the response. Service as of this date by the Clerk of Court. [939560] [LMS] [Entered: 07/31/2023 02:44 PM] (2) |
| Jul 27, 2023 | 31 | MOTION of Regeneron Pharmaceuticals, Inc.; Ocular Therapeutix, Inc. for leave to file an amicus curiae brief. Service: 07/27/2023 by email. [938924] [22-2153] [Irena Royzman] [Entered: 07/27/2023 03:05 PM] (34) |
| Jul 27, 2023 | 30 | Certificate of Interest for Regeneron Pharmaceuticals, Inc.; Ocular Therapeutix, Inc.. Service: 07/27/2023 by email. [938910] [22-2153] [Irena Royzman] [Entered: 07/27/2023 02:53 PM] (3) |
| Jul 27, 2023 | 29 | Entry of Appearance for Irena Royzman; Christine Willgoos; Paul Brzyski as counsel for Regeneron Pharmaceuticals, Inc.; Ocular Therapeutix, Inc.. Service: 07/27/2023 by email. [938907] [22-2153] [Irena Royzman] [Entered: 07/27/2023 02:49 PM] (2) |
| Jul 24, 2023 | 28 | MODIFIED ENTRY: OPENING BRIEF FILED by Appellants Alfasigma S.p.A., Bausch Health Ireland Ltd., Salix Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd.. Service: 07/24/2023 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [938184] --[Edited 08/01/2023 by KMH - compliance review complete] Paper copies of this brief must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A). [William Peterson] [Entered: 07/24/2023 04:37 PM] (132) |
| Jun 29, 2023 | 27 | ORDER filed granting the motion [23] only to the extent that the case will be placed on the next available oral argument calendar after briefing is complete. Service as of this date by the Clerk of Court. [933287] [LMS] [Entered: 06/29/2023 04:16 PM] (2) |
| Jun 25, 2023 | 26 | REPLY of Cross-Appellant Norwich Pharmaceuticals Inc. to response [25]. Service: 06/25/2023 by email. [932061] [22-2153] [Chad Landmon] [Entered: 06/25/2023 09:15 PM] (22) |
| Jun 22, 2023 | 25 | RESPONSE of Appellants Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Alfasigma S.p.A. and Bausch Health Ireland Ltd. to Doc No. [23]. Service: 06/22/2023 by email. [931794] [22-2153] [Julie Goldemberg] [Entered: 06/22/2023 07:19 PM] (80) |
| Jun 15, 2023 | 24 | ORDER directing Salix to respond to the motion [23] no later than seven days from the date of filing of this order. Any reply is due no later than three days thereafter. Service as of this date by the Clerk of Court. [930423] [NL] [Entered: 06/15/2023 04:08 PM] (2) |
| Jun 14, 2023 | 23 | MOTION of Cross-Appellant Norwich Pharmaceuticals Inc. to expedite briefing schedule. Service: 06/14/2023 by email. [930076] [22-2153] [Chad Landmon] [Entered: 06/14/2023 04:26 PM] (49) |
| Jun 14, 2023 | 22 | Amended Entry of Appearance for Chad Landmon; Matthew Murphy; Thomas Hedemann; Matthew Becker; Rebecca Clegg as counsel for Cross-Appellant Norwich Pharmaceuticals Inc.. Service: 06/14/2023 by email. [930074] [22-2153] [Chad Landmon] [Entered: 06/14/2023 04:23 PM] (4) |
| Jun 13, 2023 | 21 | Official caption revised to reflect cross-appeal 23-1952. (see attached). Service as of this date by the Clerk of Court. [929731] [KMH] [Entered: 06/13/2023 02:40 PM] (2) |
| Jun 13, 2023 | 20 | Note to File: The following cases are consolidated: 22-2153 Lead with 23-1952 Cross-Appeal. The parties must file all documents in the lead appeal only. [929730] [22-2153, 23-1952] [KMH] [Entered: 06/13/2023 02:39 PM] (0) |
| May 24, 2023 | 19 | ORDER reactivating case under FRAP 4(a)(4). Appellants' brief is due 07/24/2023. Service as of this date by the Clerk of Court. [925558] [KMH] [Entered: 05/24/2023 10:25 AM] (2) |
| May 24, 2023 | 18 | Amended docket sheet from United States District Court for the District of Delaware. [925550] [KMH] [Entered: 05/24/2023 10:14 AM] (24) |
| Apr 17, 2023 | 17 | Amended Entry of Appearance for William R. Peterson; Michael J. Abernathy; Julie S. Goldemberg; Michael T. Sikora; Scott K. Reed; Steven C. Kline; Shannon K. Clark; Karon N. Fowler; Joshua Daniel Calabro; Becky E. Steephenson; Alexis M. McJoynt as counsel for Appellants Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Bausch Health Ireland Ltd. and Alfasigma S.p.A.. Service: 04/17/2023 by email. [917329] [22-2153] [William Peterson] [Entered: 04/17/2023 07:22 PM] (3) |
| Oct 14, 2022 | 16 | Clerk's Notice to the Originating Tribunal: Upon disposition of the motion(s) subject to FRAP 4(a)(4), please transmit a certified copy of the docket entries. Service as of this date by the Clerk of Court. [877877] [KMH] [Entered: 10/14/2022 11:59 AM] (1) |
| Oct 14, 2022 | 15 | ORDER The motions, [12] and [14], are granted to the extent that the appeal is deactivated. Within 30 days of the district court's disposition of the Rule 60(b) motion, the parties are directed to inform the court how they believe this appeal should proceed.. Service as of this date by the Clerk of Court. [877842] [NL] [Entered: 10/14/2022 11:19 AM] (2) |
| Oct 10, 2022 | 14 | MOTION of Appellants Salix Pharmaceuticals, Inc., Salix Pharmaceuticals, Ltd., Bausch Health Ireland Ltd. and Alfasigma S.p.A. to extend the time to 12/23/2022 to file brief. Service: 10/10/2022 by email. [876831] [22-2153] [William Peterson] [Entered: 10/10/2022 06:02 PM] (12) |
| Oct 4, 2022 | 13 | Notice from Appellants Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Bausch Health Ireland Ltd. and Alfasigma S.p.A. regarding postjudgment motions. Service: 10/04/2022 by email. [875749] [22-2153] [William Peterson] [Entered: 10/04/2022 01:22 PM] (6) |
| Sep 23, 2022 | 12 | MODIFIED ENTRY: MOTION of Appellants Alfasigma S.p.A., Bausch Health Ireland Ltd., Salix Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. to stay appeal. Service: 09/23/2022 by email. [873794]--[Edited 09/27/2022 by JCA - Reason: to correct filing event] [William Peterson] [Entered: 09/23/2022 05:58 PM] (8) |
| Sep 23, 2022 | 11 | Amended Certificate of Interest for Appellants Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Bausch Health Ireland Ltd. and Alfasigma S.p.A.. Service: 09/23/2022 by email. [873789] [22-2153] [William Peterson] [Entered: 09/23/2022 05:32 PM] (3) |
| Sep 23, 2022 | 10 | Amended Entry of Appearance for William R. Peterson; Michael J. Abernathy; Julie S. Goldemberg; Michael T. Sikora; Scott K. Reed; Steven C. Kline; Shannon K. Clark; Karon N. Fowler; Joshua Daniel Calabro; Becky E. Steephenson; Alexis M. McJoynt as counsel for Appellants Salix Pharmaceuticals, Inc., Salix Pharmaceuticals, Ltd., Bausch Health Ireland Ltd. and Alfasigma S.p.A.. Service: 09/23/2022 by email. [873787] [22-2153] [William Peterson] [Entered: 09/23/2022 05:31 PM] (3) |
| Sep 20, 2022 | 9 | Corrected Entry of Appearance for William R. Peterson; Michael J. Abernathy; Julie S. Goldemberg; Michael T. Sikora; Scott K. Reed; Steven C. Kline; Shannon K. Clark; Karon N. Fowler as counsel for Appellants Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Bausch Health Ireland Ltd. and Alfasigma S.p.A.. Service: 09/20/2022 by email. [872801] [22-2153] [William Peterson] [Entered: 09/20/2022 02:37 PM] (3) |
| Sep 13, 2022 | 8 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Alfasigma S.p.A., Bausch Health Ireland Ltd., Salix Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd., Entry of Appearance [2], is not in compliance with the rules of this court (see attached). Compliant document due on 09/20/2022. Service as of this date by the Clerk of Court. [871484] [KMH] [Entered: 09/13/2022 03:49 PM] (2) |
| Sep 8, 2022 | 7 | Docketing Statement for the Appellee Norwich Pharmaceuticals Inc.. Service: 09/08/2022 by email. [870811] [22-2153] [Matthew Murphy] [Entered: 09/08/2022 05:59 PM] (4) |
| Sep 8, 2022 | 6 | Certificate of Interest for Appellee Norwich Pharmaceuticals Inc.. Service: 09/08/2022 by email. [870809] [22-2153] [Matthew Murphy] [Entered: 09/08/2022 05:58 PM] (5) |
| Sep 8, 2022 | 5 | Entry of appearance for Chad A. Landmon; Matthew S. Murphy as counsel for Appellee Norwich Pharmaceuticals Inc.. Service: 09/08/2022 by email. [870808] [22-2153] [Matthew Murphy] [Entered: 09/08/2022 05:58 PM] (4) |
| Sep 8, 2022 | 4 | Docketing Statement for the Appellants Salix Pharmaceuticals, Inc., Salix Pharmaceuticals, Ltd., Bausch Health Ireland Ltd. and Alfasigma S.p.A.. Service: 09/08/2022 by email. [870663] [22-2153] [William Peterson] [Entered: 09/08/2022 01:32 PM] (4) |
| Sep 8, 2022 | 3 | Certificate of Interest for Appellants Salix Pharmaceuticals, Inc., Salix Pharmaceuticals, Ltd., Bausch Health Ireland Ltd. and Alfasigma S.p.A.. Service: 09/08/2022 by email. [870661] [22-2153] [William Peterson] [Entered: 09/08/2022 01:31 PM] (5) |
| Sep 8, 2022 | 2 | Entry of appearance for William R. Peterson; Michael J. Abernathy; Julie S. Goldemberg; Michael T. Sikora; Scott K. Reed; Steven C. Kline; Shannon K. Clark; Karon N. Fowler as counsel for Appellants Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Bausch Health Ireland Ltd. and Alfasigma S.p.A.. Service: 09/08/2022 by email. [870659] [22-2153] [William Peterson] [Entered: 09/08/2022 01:30 PM] (5) |
| Aug 25, 2022 | 1 | Appeal docketed. Received: 08/17/2022. [868235]Entry of Appearance due 09/08/2022. Certificate of Interest is due on 09/08/2022. Docketing Statement due 09/08/2022. Appellant/Petitioner's brief is due 10/24/2022. [KMH] [Entered: 08/25/2022 09:31 AM] (31) |
